Jacobs & Co. CA Boosts Position in Edwards Lifesciences Co. (NYSE:EW)

Jacobs & Co. CA grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 110,665 shares of the medical research company’s stock after acquiring an additional 3,447 shares during the period. Jacobs & Co. CA’s holdings in Edwards Lifesciences were worth $8,438,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Castleview Partners LLC purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $25,000. Compass Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $31,000. Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $38,000. Janiczek Wealth Management LLC raised its holdings in Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after purchasing an additional 303 shares in the last quarter. Finally, Sunbelt Securities Inc. purchased a new stake in Edwards Lifesciences during the first quarter valued at approximately $49,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. Truist Financial increased their price target on Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Stifel Nicolaus raised their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a report on Wednesday, February 7th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Citigroup lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Monday, December 11th. Finally, Royal Bank of Canada upped their target price on Edwards Lifesciences from $82.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $88.50.

Insider Buying and Selling

In other news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 10,000 shares of the firm’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $75.67, for a total transaction of $756,700.00. Following the completion of the transaction, the vice president now owns 39,503 shares of the company’s stock, valued at $2,989,192.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. Insiders sold a total of 196,859 shares of company stock worth $16,445,296 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 1.9 %

Shares of NYSE:EW opened at $95.15 on Thursday. The company’s 50 day moving average is $85.48 and its two-hundred day moving average is $75.86. The company has a market cap of $57.21 billion, a PE ratio of 41.37, a P/E/G ratio of 4.63 and a beta of 1.05. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $95.35. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.64 EPS. Equities analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.